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Abstract
Background: The study aim is to estimate sensitivity and specificity of anal cytology for histologic HSIL in analyses adjusted
for the imperfect biopsy reference standard.
Methods and Principal Findings: Retrospective cohort study of an anal dysplasia screening program for HIV infected adults.
We estimated the prevalence of histologic HSIL by concurrent cytology category and the associated cytology ROC area.
Cytology operating characteristics for HSIL were estimated and adjusted for the imperfect reference standard by 3
methodologies. The study cohort included 261 patients with 3 available measures: (1) referral cytology; (2) HRA cytology;
and (3) HRA directed biopsy. The prevalence of biopsy HSIL varied according to the concurrent HRA cytology result: 64.5%
for HSIL or ASC-H, 12.6% for LSIL, 10.9% for ASCUS, and 6.3% for no abnormality. The cytology ROC area was 0.78. The
observed prevalence of HSIL was 37% (referral cytology), 24% (HRA cytology), and 24% (HRA biopsy). Unadjusted estimates
of sensitivity and specificity of cytology were 0.66 and 0.90, respectively. Adjusted estimates varied from 0.47–0.89
(sensitivity) and 0.89—1.0 (specificity).
Conclusions: Analysis of a single dataset yields widely different estimates of anal cytology operating characteristics that
depend on difficult to verify assumptions regarding the accuracy of the imperfect reference standard.
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Introduction
In a systematic review dealing with screening HIV-infected
individuals for precursors of anal cancer, Chiao et al. reported
that, among studies using similar methodology, the operating
characteristics of anal cytological examination for high resolution
anoscopy (HRA) directed biopsy varied from 69% to 93%
(sensitivity) and from 32% to 59% (specificity) [1]. The low
reported specificity implies a high false positive rate for cytology.
However, this inference is flawed because it assumes that the
reference standard, HRA-directed biopsy is a perfect gold
standard that results in no misclassification of true disease status.
Our study aim was to estimate the sensitivity and specificity of anal
cytology for high grade anal dysplasia in analyses adjusted and
unadjusted for the imperfect nature of the reference standard
(HRA directed anal biopsy).
Methods
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the University of California at San
Diego (UCSD) Human Research Protection Program, project#
071931. All patients provided written informed consent for the
collection of samples and subsequent analysis.
In July 2000, the Owen Clinic, the adult HIV clinic at UCSD
Medical Center in San Diego, implemented routine screening for
anal cancer and its precursors. Clinic protocol advises primary
care providers to perform a digital rectal examination and obtain
anal cytology on all new patients and thereafter annually. Patients
found to have abnormal cytology (any results other than ‘‘no
atypical or malignant cells’’), abnormalities on digital rectal
examination, or anorectal symptoms are referred for HRA.
Previous publications from the Owen Clinic dysplasia cohort
described findings from the initial implementation phase [2] and
from a comprehensive evaluation of the screening program
through 2005 [3]. The current retrospective cohort analysis
includes cytologic and histopathologic results from screening
procedures performed between May 2007–October 2009. The
analytic data set includes 3 primary variables: (1) the referral
cytology (obtained by the primary care provider as the first stage of
screening); (2) the HRA cytology (obtained by the HRA operator
at the time of high resolution anoscopy); and (3) punch biopsy
(obtained using a baby Tischler forceps at time of HRA). Cytology
specimens were obtained with a moistened Dacron swab (PurFybr,
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Test system [4,5]. High resolution anoscopy was performed by
four internists following a previously described protocol [6]. The
number of biopsies obtained was operator dependent. For analyses
presented here, the most severe histologic category was assigned if
multiple biopsies were performed. Both cytologic and histopath-
ologic categories were assigned using the 2001 Bethesda System
for reporting cervical cytology [7].
Following presentation of descriptive results, we present the
prevalence of biopsy high grade dysplasia according to HRA
cytology result and the associated receiver operating characteristic
(ROC) [8] area for high grade dysplasia on biopsy as the cytology
cut point is varied across 4 result categories: (1)high grade
squamous intraepithelial lesion (HSIL) or atypical squamous cells
can’t rule out high grade (ASC-H); (2) low grade squamous
intraepithelial lesion (LSIL); (3) atypical squamous cells of
uncertain significance (ASCUS); (4) no atypical or malignant cells
(NAMC). We then present estimates of the operating character-
istics (sensitivity [SE], specificity [SP], likelihood ratio positive
[LRP], and likelihood ratio negative [LRN]) of binary coded HRA
cytology (cut point at high grade vs. not high grade) for HSIL on
biopsy. Histopathologically, HSIL includes the categories of
moderate dysplasia (anal intraepithelial neoplasia 2 [AIN 2]),
severe dysplasia (AIN 3) and carcinoma-in-situ (CIS). These
operating characteristics are presented first without adjustment,
assuming that punch biopsy diagnosis defines true disease status.
Recognizing that the yield of both cytology and biopsy are
operator dependent, we present the unadjusted sensitivity and
specificity separately by anoscopist and also pooled across
anoscopists using a random effects meta analytic model imple-
mented in Stata 11.0 (Stata Corporation, College Station, Texas).
We then present three adjusted estimates of cytology sensitivity
and specificity.
The first adjustment assumes: (1) that anal punch biopsy is itself
measured with error and has the same sensitivity and specificity for
histopathologic anal HSIL as was reported for histopathologic
cervical HSIL by Byrom et al.[9], who compared cervical punch
biopsy to LLETZ (large loop excision of the transformation zone)
as a reference standard; and (2) that cytology and punch biopsy are
conditionally independent given true disease status [10]. Byrom
reported that the sensitivity and specificity of colposcopically
directed punch biopsy for high-grade CIN (defined as CIN 2 or
CIN 3) was 74% and 91%, respectively [9]. Staquet et al. derived
equations (equations 8 {SN~
azc ðÞ SPR{c
N SPR{1 ðÞ z azb ðÞ
}and 9
{SPN~
bzd ðÞ SR{b
NSR{ azb ðÞ
}) [11] to estimate the sensitivity and
specificity of a new test when: (1) the reference standard is
imperfect but with known sensitivity and specificity and (2) the new
test and the reference standard are conditionally independent
given true disease status.
The second adjustment assumes that the punch biopsy has
unknown sensitivity but 100% specificity. Although the assump-
tion of 100% specificity for punch biopsy is only approximately
true, it could be justified from a clinical perspective in that there is
more concern with HRA sampling error (reducing biopsy
sensitivity) than with false positive biopsy results. The assumption
of 100% specificity amounts to an assumption that punch biopsy
yields pathognomonic results. If this assumption is justified, then
Staquet has shown that the sensitivity of new test (here anal
cytology) is estimated without bias, but that specificity, positive
predictive value, and disease prevalence are underestimated while
negative predictive value is overestimated. Staquet has shown
further that, under this scenario, ‘‘the true value of the specificity
of the new test is confined between 100% and a lower bound
which is the observed specificity (of the new test)’’ [11]. If equation
19 in Staquet’s publication is solved for test specificity, the
dependence of test specificity on disease prevalence can be easily
explored (see Appendix S1).
The third adjustment is based on latent class analysis (LCA), a
statistical method for combining test results (here referral cytology,
HRA cytology, and HRA biopsy) to estimate the true but
unknown disease status (HSIL or not HSIL). This approach has
the advantage of taking into account information from multiple
sources in estimating true disease status but, in its traditional form,
requires a minimum of three conditionally independent tests
[10,12]. LCA is part of a family of statistical models known as
mixture models and is a categorical data analog of the continuous
variable methodology of factor analysis. As with other latent
variable techniques, LCA postulates the existence of an error-free
latent variable (in our case the presence or absence of HSIL in
anal canal tissue) and estimates the value of this latent variable by
modeling, commonly through the expectation-maximization (EM)
algorithm, observed variables that are themselves subject to
measurement error (here anal cytology and HRA directed punch
biopsy). Accessible introductions to LCA methodology are
available [13,14]. In utilizing LCA to model sensitivity and
specificity of HRA cytology, we imposed the clinically sensible
restriction that when the HRA directed biopsy showed HSIL, that
diagnosis was considered to be known with certainty. If the biopsy
did not show HSIL, the LCA model was allowed to assign a value
to the latent disease status based on information from all three
indicator variables (referral cytology, HRA cytology, and HRA
biopsy). We report the sensitivity and specificity estimates from: (1)
the 7-parameter LCA model without relaxation of the conditional
independence assumption and (2) the 10-parameter model that
relaxes the conditional independence assumption by allowing
estimation of direct effects among the three pairs of indicator
variables. These LCA models were estimated using Latent Gold
4.5 (Statistical Innovations, Inc., Belmont, MA).
Finally, we present a sensitivity analysis of the impact of the
varying estimates of unadjusted and adjusted HRA cytology
operating characteristics on the post test probability of anal HSIL
disease. This analysis illustrates the range of uncertainty regarding
the probability that a patient with a non-HSIL anal cytology result
actually harbors HSIL changes if that patient was selected from a
population with known HSIL prevalence.
Results
Between 1 May 2007 and 21 October 2009, 407 HIV infected
patients underwent HRA with biopsy. By sex, 93% were male;
42% were non-white. By HIV transmission risk factor, 70% were
men having sex with men (MSM) and 13% were injection drug
users (not MSM). Their median age (IQR) was 45 (39–51) years.
Median (IQR) CD4 and HIV plasma viral load were 429 (261–
611) cell/mL and 1.70 (1.68–2.14) log10 copies/mL, respectively.
Of the 407 who underwent HRA-directed biopsy, 371 (91%) had a
concurrent HRA cytology and 261 (64%) had both a referral and
HRA cytology available for analysis. For consistency, analyses will
be restricted to the 261 patients with complete data on the 3
primary variables (referral cytology, HRA cytology, and HRA
directed biopsy). For this set of patients, the observed prevalence of
HSIL was 37% (referral cytology), 24% (HRA cytology), and 24%
(HRA biopsy). The prevalence of biopsy HSIL varied according to
the concurrent HRA cytology result: 64.5% (40/62) for HSIL or
ASC-H, 12.6% (13/103) for LSIL, 10.9% (7/64) for ASCUS, and
6.3% (2/32) for NAMC. The receiver operating characteristic
Anal Cytology and HIV
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ASC-H, LSIL, ASCUS, NAMC) for HSIL on biopsy was 0.78
(95% CI: 0.72–0.85). The median (IQR) time between referral
and HRA cytologies for the 261 patients in the analysis was 158
(66,295) days, with a range of 2 to 839 days. We categorized both
cytology and biopsy results into corresponding binary groups as
follows: (1) for cytology, (HSIL or ASC-H) vs. (LSIL, ASCUS,
atypia, or NAMC); for biopsy, (AIN 2, AIN 3, or CIS) vs. (normal
mucosa or AIN 1). Table 1 presents the cross classification of the
three binary coded primary analytic variables.
Figure 1 presents the unadjusted sensitivity and specificity of
HRA cytology for HSIL on HRA-directed biopsy, separately by
anoscopist and then pooled over anoscopists. There was no
statistical evidence of heterogeneity of effect across anoscopists for
either sensitivity or specificity (I-squared p-values 0.136 and 0.237,
respectively). The pooled sensitivity (95% CI) and specificity (95%
CI) of binary coded HRA cytology (HSIL vs. not HSIL) were 0.66
(0.50–0.81) and 0.90 (0.85–0.95), respectively.
The first adjustment of HRA cytology sensitivity and specificity
involves an extrapolation from the findings of Byrom et al.[9]
regarding the sensitivity and specificity of colposcopically directed
cervical punch biopsy in the detection of HSIL by the LLETZ
procedure (taken as a gold standard). Assuming that the sensitivity
and specificity of HRA directed anal biopsy for true HSIL is the
same as reported by Byrom (74% and 91%, respectively) and also
assuming the conditional independence of HRA cytology and
HRA biopsy given true disease status, we found the corrected
sensitivity and specificity of HRA cytology to be 89% and 96%,
respectively (Table 2).
The second adjustment of HRA cytology sensitivity and
specificity assumes that HRA biopsy yields pathognomonic results
(no false positives). If the observed prevalence of HSIL disease by
biopsy (24%) reflects the true prevalence, then the adjusted
estimates for HRA cytology sensitivity and specificity are 0.66
(same as the unadjusted sensitivity) and 0.89, respectively (Table 2).
As the true prevalence of HSIL disease varies from 24% to 37%,
the specificity of HRA cytology varies from 0.89 to 1.00,
illustrating the findings of Staquet et al. regarding the dependence
of test specificity on disease prevalence when the reference test
(HRA biopsy) is assumed to have 100% specificity.
The third adjustment utilizes latent class analysis to estimate
HRA cytology sensitivity and specificity from a probabilistic model
including the joint binary distributions of the 3 indicator variables
(referral cytology, HRA cytology, and HRA biopsy) and imposing
the assumption that when the HRA biopsy is read as HSIL, the
true disease state is considered to be known (no false positives).
Results from two models are presented in Table 2 (labeled 3 and
39). The first LCA model (column 3) assumed conditional
independence and resulted in HRA cytology sensitivity and
specificity estimates of 0.74 and 1.0, respectively. In contrast,
after relaxing the conditional independence assumption (column
39), the estimate of HRA cytology sensitivity dropped to 0.47.
Review of the classification tables for models 3 and 39 reveals that
the only difference in LCA cluster (latent disease status) assignment
between the two models is for the combination of test results:
referral cytology ‘‘HSIL or ASC-H’’, HRA cytology ‘‘, HSIL’’,
and HRA biopsy ‘‘,HSIL’’ (n=47 out of 261). Model 3
(conditional independence assumed) assigned cases with this result
combination to a true disease status of ‘‘,HSIL’’, whereas model
39 (relaxed conditional independence assumption) assigned the
same cases to the ‘‘HSIL’’ category. The corresponding LCA
estimates for true HSIL disease prevalence are 32% [84/261]
(model 3) and 50% [131/261](model 39), contrasted with the
observed HSIL biopsy prevalence of 24% that is assumed to be
accurate when punch biopsy is considered to be a true gold
standard.
Finally, Figure 2 presents a sensitivity analysis of the impact of
the varying estimates of HRA cytology operating characteristics
(shown in Table 2) on the post test probability of true anal HSIL
changes after a single non-HSIL cytology result. The figure
expresses the cytology operating characteristics as a negative
likelihood ratio (defined as [1– sensitivity/specificity]), which is
interpretable as a measure of how much less likely someone with
true HSIL is to have a non-HSIL cytology compared to someone
without HSIL tissue changes. As an example, if the true
prevalence of anal HSIL in the studied population was 20%, the
post test probability of HSIL changes after a non-HSIL cytology
varies from 2.9% (LRN = 0.12) to 11.7% (LRN = 0.53).
Discussion
Depending upon what assumptions are made regarding the
sensitivity and specificity of HRA directed punch biopsy for true
anal HSIL, we found that the estimated sensitivity of anal cytology
could range from 47% to 89%. The width of this range (42) based
on analysis of the same dataset is wider than the range of 24 noted by
Chiao et al.[1] in their summary of unadjusted anal cytology
operating characteristics from 6 different datasets derived from
studies using similar methodologies and highlights the importance
of understanding the accuracy of the reference standard (HRA
directed punch biopsy) in evaluating the accuracy of a screening
test (anal cytology).
Implications for screening policy of our adjusted analyses of anal
cytology operating characteristics are suggested in Figure 2 if one
asks the question ‘‘Is the post-test probability of true high grade
anal dysplasia sufficiently low after a non-HSIL anal cytology that
Table 1. Cross classification of referral cytology, HRA cytology, and HRA directed biopsy (n=261 patients).
Biopsy and HRA cytology
Referral Cytology Biopsy , AIN 2 Biopsy $ AIN 2
Cytology , HSIL
Cytology HSIL
or ASC-H Cytology , HSIL
Cytology HSIL
or ASC-H
Cytology ,HSIL 130 9 12 14 165 (63%)
Cytology HSIL or ASC-H 47 13 10 26 96 (37%)
177 (68%) 22 (8.5%) 22 (8.5%) 40 (15%) 261 (100%)
HRA: high resolution anoscopy; AIN: anal intraepithelial neoplasia; HSIL: high grade squamous intraepithelial lesion; ASC-H: atypical squamous cells, can’t rule out high
grade.
doi:10.1371/journal.pone.0012284.t001
Anal Cytology and HIV
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answer would require information on several factors: (1) the
prevalence of true HSIL in the population under care; (2)the
cytology operating characteristics; (3) the accuracy of HRA
diagnosis of high grade disease; (4) the frequency of cytology
screening; (5) the rate of disease progression between screenings;
and (6) the availability and effectiveness of ablative treatments for
HSIL in reducing risk of invasive anal cancer. Figure 2 illustrates
that the variation (attributable to assumptions regarding reference
standard accuracy) in estimated probability of missing true HSIL
changes is smallest at low disease prevalence and increases through
plausible estimates of disease prevalence. Unbiased estimates of
HSIL prevalence among HIV infected populations are difficult to
obtain. Palefsky et al. reported a 4-year incidence of AIN 2 or AIN
3 of 38% in an observational cohort of HIV-infected MSM
recruited in the pre-HAART era in San Francisco [15]. Anderson
et al. reported a prevalence of anal HSIL of 13% in a clinic based
cohort of HIV-infected patients (98% male) with entry CD4 .300
cells/mL [16]. The prevalence of anal HSIL among MSM without
HIV infection has been estimated to be approximately 5% [17]. In
an unselected population of HIV-infected patients (92% male and
68% MSM) under care, we found a cytologic prevalence of HSIL
of 7.5% at initial screening cytology [2]. So the plausible range of
cytologic HSIL prevalence among HIV infected male populations
may vary from 5% to 38%, varying by risk factors and degree of
immunosuppression. Especially toward the higher end of this
range, the estimates in Figure 2 would suggest considerable
uncertainty regarding how many true HSIL cases would be
undiagnosed by deferring HRA among patients with non-HSIL
screening cytology.
Figure 1. Sensitivity and specificity of HRA cytology for HSIL on biopsy (n=261 exams), by anoscopist and pooled overall.
doi:10.1371/journal.pone.0012284.g001
Table 2. Unadjusted and adjusted estimates of sensitivity,
specificity, LRP1, and LRN11 of HRA cytology for HSIL on HRA
directed biopsy (n=261 patients).
Unadjusted Adjusted
123 3 9
Sensitivity 0.66 0.89 0.66 0.74 0.47
Specificity 0.90 0.96 0.89 1.0 1.0
*LRP 6.6 22.25 6.0 ‘‘
{LRN 0.38 0.12 0.38 0.26 0.53
*LRP: likelihood ratio positive [sensitivity/(1– specificity)].
{LRN: likelihood ratio negative [(1– sensitivity)/specificity].
1. Adjusted assuming: (1) sensitivity and specificity of biopsy for HSIL are 0.74
and 0.91, respectively (from Byrom et al.[9]) and (2) conditional independence
between cytology and biopsy given true disease status.
2. Adjusted assuming that HRA-directed biopsy has 100% specificity but unknown
sensitivity. Then the sensitivity of HRA cytology is estimated without bias as the
observed sensitivity (0.66) and the specificity of HRA cytology is estimated by
solving equation 19 { Pr~
azb ðÞ N:SPN{b{d ðÞ
NS P N azb ðÞ {b ½ 
}o fS t a q u e te ta l . [ 1 1 ]f o r
specificity. Here we assumed the observed HSIL prevalence of 24% by biopsy.
3. Adjusted using latent class analysis (LCA) assuming conditional
independence but imposing restriction that HRA biopsy result of HSIL is
measured without error (no false positives).
39. Adjusted using latent class analysis (LCA) relaxing conditional independence
assumption and imposing restriction that HRA biopsy result of HSIL is measured
without error (no false positives).
doi:10.1371/journal.pone.0012284.t002
Anal Cytology and HIV
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characteristicsofcervicalpunchbiopsytoanalpunch biopsyismore
properly considered a hypothesis based on: (1) the common viral
pathogenesis of cervical and anal dysplasia [18]; (2) the homologous
natureofthe cervicaland anal transformation zones;(3)comparable
diagnostic categories for both cervical and anal dysplasia (modified
Bethesda system for CIN and AIN) [7]; (4) the comparability of
screening procedures [1]; and (5) the comparability of colposcopic
and HRA visual indications of underlying dysplasia [19]. An
important difference between the anatomy of the anal canal and of
the uterine cervix is the cylindrical collapsing nature of the anal
canal, a characteristic which limits full visualization under
magnified examination and may reduce the sensitivity of anal
punch biopsy in comparison to that of cervical punch biopsy.
Which of our estimates of the sensitivity and specificity of anal
cytology are best? The frank answer is that we don’t know.
However, we lean toward the adjusted estimate of Model 1
(Table 2) that is based on extrapolation from the measured
sensitivity and specificity of cervical punch biopsy and on the
assumption of conditional independence of cytology and biopsy
results given true disease status. Unfortunately, neither of the
assumptions involved in this estimate are directly verifiable. But
the estimates from Model 1 (sensitivity 89%, specificity 96%) are
similar to those derived from Model 3 (sensitivity 74% and
specificity 100%), the latent class model assuming conditional
independence and also that HRA biopsy result had no false
positives. The limitations of the application of latent class analysis
to diagnostic test evaluation have been recently reviewed [12,20]
and include the following challenges: (1) the presence or absence of
the disease being studied (in this case anal dysplasia) is defined
statistically, not clinically; (2) the assumptions of the method are
often not directly testable. An advantage of LCA is that it allows
use of multiple sources of information in defining disease status,
and this is conceptually appealing in our application where
screening both by cytology and HRA are typically repeated at
varying intervals and the replications can provide additional
information regarding true disease status. However, not all
preceding replicate tests are of equal value. In previous work
[2], we reported that agreement between sequential anal cytology
results decreased as the interval between measurements increased,
a phenomenon that probably reflects biological evolution over
time. Restricting eligibility of referral cytology for inclusion in the
analysis to an interval of three to six months from HRA would
strengthen the association between referral cytology and HRA
measurements but at the cost of reduced sample size and selection
bias as those with longer intervals between measurements tend to
be those with lower degrees of dysplasia on referral cytology.
In a recent review of anal cytology screening, Ho and Cranston
expressed the opinion that the ‘‘poor specificity limits the utility of
anal cytology as a screening tool given that many patients without
high-grade dysplasia will be referred for HRA, resulting in
increased healthcare delivery cost and excessive use of clinical
resources’’ [21]. However, this inference would seem to be based
on the assumption that the HRA directed punch biopsy represents
a true gold standard and that, consequently, a high grade cytology
matched with a less than high grade biopsy represents a false
positive cytology. We believe that the wide reported ranges of
sensitivity and specificity for anal cytology are likely to be
Figure 2. Post test and pretest probabilities of anal HSIL for non-HSIL cytology result, by cytology negative likelihood ratios (LRN).
doi:10.1371/journal.pone.0012284.g002
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extent of disease sampled by both cytology and biopsy. We
previously reported a positive association between number of
HRA procedures performed and kappa agreement between
cytology and biopsy [3]. Regarding disease burden, Nathan et
al. recently demonstrated the dependency of anal cytology
operating characteristics upon the extent of disease noted at high
resolution anoscopy [22].
Ouranalysesaresubjecttoa numberoflimitations.First,theyare
based on observational data subject to selection bias. Consistent
with published recommendations [23], not all patients who
underwent screening cytology were referred for HRA. In particular
there was under representation of patients with no abnormalities on
screening cytology. Second, our choice of cytology result cut point
(HSIL vs. not HSIL) for the primary analyses of cytology sensitivity
and specificity allowed examination of only one point on the ROC
curve that summarizes the tradeoff between sensitivity and
specificity as the cytology cut point is varied. The overall ROC
area estimated for anal cytology in this study (0.78) suggests similar
discriminatory ability to comparable estimates of the accuracy of
cervical cytology (ROC areas calculated from 2 publications with
analyzable data 0.79 [24] and 0.94 [25]). Third, in modeling the
corrected operating characteristics of anal cytology we accepted the
pathologist’s clinical report as itself reliable. However, this approach
neglects important variability within and among pathologists in
reading the same cytology and biopsy specimens [26]. As Lytwyn et
al. have demonstrated, the kappa agreement among four indepen-
dently reading pathologists with a consensus diagnosis distinguish-
ingHSILfrom non-HSIL varied from 0.55 to 0.88for anal cytology
andfrom0.76to0.94foranalpunchbiopsyspecimens[26].Fourth,
as latent class analysis requires a minimum of three estimators of the
value of the latent class variable, we used the referral cytology as the
third estimator in addition to concurrently obtained HRA cytology
and HRA punch biopsy. However, only 64% of those who
underwent HRA biopsy had both referral and HRA cytology
available for analysis.
Inconclusion,inadvancingtheevidencebaseofscreeningforanal
cancer and its precursors among patient populations at increased
risk, it is important to characterize the operating characteristics of
each screening component. The measurement of the accuracy of the
first component of screening, anal cytological examination, should
take into account the fact that the most commonly available
reference test, HRA-directed punch biopsy, is itself subject to
sampling and measurement error. While there is no single
adjustment that unequivocally solves the problem, our analyses
under varying assumptions illustrate the range of uncertainty
associated with empirical estimates of cytology sensitivity, specificity,
and predictive values. Screening policy recommendations should
take into account that both anal cytology and HRA evaluation with
biopsy provide valuable but fallible complementary information
regarding the true extent of dysplasia in the anal canal.
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